Treatment patterns and use of resources in patients with tuberous sclerosis complex: Insights from the TOSCA registry
Ruben Marques
(1, 2)
,
Elena Belousova
(3)
,
Mirjana P. Benedik
(4)
,
Tom Carter
(5)
,
Vincent Cottin
(6)
,
Paolo Curatolo
(7)
,
Maria Dahlin
(8)
,
Lisa d'Amato
(1)
,
Guillaume Beaure d'Augères
(9)
,
Petrus J. De Vries
(10)
,
Jose C. Ferreira
(11)
,
Martha Feucht
(12)
,
Carla Fladrowski
(13)
,
Christoph Hertzberg
(14)
,
Sergiusz Jozwiak
(15)
,
John A. Lawson
(16)
,
Alfons Macaya
(17)
,
Rima Nabbout
(18, 19)
,
Finbar O'Callaghan
(20)
,
Jiong Qin
(21)
,
Valentin Sander
(22)
,
Matthias Sauter
(23)
,
Seema Shah
(1)
,
Yukitoshi Takahashi
(24)
,
Renaud Touraine
(25)
,
Sotiris Youroukos
(26)
,
Bernard Zonnenberg
(27)
,
John C. Kingswood
(28)
,
Anna C. Jansen
(29)
1
Novartis Pharma AG
2 Universidad de León [León]
3 Pirogov Russian National Reasearch Medical University Moscow
4 UMCL - University Medical Centre Ljubljana [Ljubljana, Slovenia]
5 TSA Tuberous Sclerosis Association, Nottingham, United Kingdom,
6 Hôpital Louis Pradel [CHU - HCL]
7 Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
8 Karolinska Institutet [Stockholm]
9 Association Sclérose Tubéreuse de Bourneville (Gradignan)
10 University of Cape Town
11 Centro Hospitalar de Lisboa Central E.P.E
12 Medizinische Universität Wien = Medical University of Vienna
13 Universitätsklinik für Kinder-und Jugendheilkunde
14 VKN - Vivantes Klinikum Neukölln [Berlin, Germany]
15 Medical University of Warsaw - Poland
16 Sydney Children's hospital
17 Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebron
18 Hôpital Necker - Enfants Malades [AP-HP]
19 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
20 Institute of Child Health [London]
21 PKUPH - People's Hospital of Peking University
22 Tallinn Children's Hospital [Tallinn, Estonia]
23 Klinikverbund Kempten-Oberallgäu gGmbH
24 University of Shizuoka
25 Service de Génétique Clinique Chromosomique et Moléculaire
26 St. Sophia Children’s Hospital, Athens
27 Department of Clinical Genetics
28 St George’s University Hospitals
29 VUB - Vrije Universiteit Brussel
2 Universidad de León [León]
3 Pirogov Russian National Reasearch Medical University Moscow
4 UMCL - University Medical Centre Ljubljana [Ljubljana, Slovenia]
5 TSA Tuberous Sclerosis Association, Nottingham, United Kingdom,
6 Hôpital Louis Pradel [CHU - HCL]
7 Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
8 Karolinska Institutet [Stockholm]
9 Association Sclérose Tubéreuse de Bourneville (Gradignan)
10 University of Cape Town
11 Centro Hospitalar de Lisboa Central E.P.E
12 Medizinische Universität Wien = Medical University of Vienna
13 Universitätsklinik für Kinder-und Jugendheilkunde
14 VKN - Vivantes Klinikum Neukölln [Berlin, Germany]
15 Medical University of Warsaw - Poland
16 Sydney Children's hospital
17 Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebron
18 Hôpital Necker - Enfants Malades [AP-HP]
19 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
20 Institute of Child Health [London]
21 PKUPH - People's Hospital of Peking University
22 Tallinn Children's Hospital [Tallinn, Estonia]
23 Klinikverbund Kempten-Oberallgäu gGmbH
24 University of Shizuoka
25 Service de Génétique Clinique Chromosomique et Moléculaire
26 St. Sophia Children’s Hospital, Athens
27 Department of Clinical Genetics
28 St George’s University Hospitals
29 VUB - Vrije Universiteit Brussel
Résumé
Tuberous Sclerosis Complex (TSC) is a rare autosomal-dominant disorder caused by mutations in the TSC1 or TSC2 genes. Patients with TSC may suffer from a wide range of clinical manifestations; however, the burden of TSC and its impact on healthcare resources needed for its management remain unknown. Besides, the use of resources might vary across countries depending on the country-specific clinical practice. The aim of this paper is to describe the use of TSC-related resources and treatment patterns within the TOSCA registry. A total of 2,214 patients with TSC from 31 countries were enrolled and had a follow-up of up to 5 years. A search was conducted to identify the variables containing both medical and non-medical resource use information within TOSCA. This search was performed both at the level of the core project as well as at the level of the research projects on epilepsy, subependymal giant cell astrocytoma (SEGA), lymphangioleiomyomatosis (LAM), and renal angiomyolipoma (rAML) taking into account the timepoints of the study, age groups, and countries. Data from the quality of life (QoL) research project were analyzed by type of visit and age at enrollment. Treatments varied greatly depending on the clinical manifestation, timepoint in the study, and age groups. GAB Aergics were the most prescribed drugs for epilepsy, and mTOR inhibitors are dramatically replacing surgery in patients with SEGA, despite current recommendations proposing both treatment options. mTOR inhibitors are also becoming common treatments in rAML and LAM patients. Forty-two out of the 143 patients (29.4%) who participated in the QoL research project reported inpatient stays over the last year. Data from non-medical resource use showed the critical impact of TSC on job status and capacity. Disability allowances were more common in children than adults (51.1% vs 38.2%). Psychological counseling, social services and social worker services were needed by <15% of the patients, regardless of age. The long-term nature, together with the variability in its clinical manifestations, makes TSC a complex and resource-demanding disease. The present study shows a comprehensive picture of the resource use implications of TSC.